Monday, February 27, 2017

Carl Icahn's Next Target: Bristol-Myers Squibb

https://www.forbes.com/sites/adamsarhan/2017/02/22/carl-icahns-next-target-bristol-myers-squibb/#7606696b3f34
--


This e-mail may be material that is confidential, privileged, and exempt from disclosure under applicable law.  If the reader of this notice is not the intended recipient or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited and the e-mail and any of the attachments must be deleted without reading or saving in any matter.

Este mensaje (incluyendo los archivos adjuntos) esta dirigido solo al receptor senalado y puede contener informacion de caracter privilegiada, privada o confidencial. Si usted no es el receptor senalado o bien ha recibido este mensaje por error, por favor notifique inmediatamente al remitente y elimine el mensaje original. Cualquier otro uso de este mensaje de correo electronico esta prohibido.

Jay S. Cohen, R.Ph., J.D.
Website: www.jaycohen.com
Member of the Ohio and U.S. Federal Bars (inactive)
Registered Pharmacist (THANKFULLY NOW INACTIVE!) in PA, NJ, KY, and IL

Owner: Elite Cruises and Travel
Luxury Cruises and Land Travel, Certified Cruise Specialists

No comments: